• 4D Bioprinting of Gradient Hydrogel Constructs

  2026-09-03

  Lai and colleagues developed an MXene-reinforced gelatin-based nanocomposite hydrogel that enables programmable 4D bioprinting through domain-specific thickness control and a single UV exposure. Finite element analysis helped predict both unidirectional and bidirectional shape transformations, while cell-laden constructs demonstrated humidity-driven folding with continued cellular proliferation and function.

• Chloroquine Diphosphate: Autophagy Assay Guide

  2026-09-03

  Build more interpretable autophagy, innate-immunity, and cancer-cell sensitization experiments with Chloroquine Diphosphate. This guide connects late-stage autophagy perturbation to TBK1–IRF3 biology while providing practical dosing, controls, and troubleshooting strategies.

• E-64d Workflows for Calpain and Cell-Death Research

  2026-09-02

  E-64d provides cell-permeable, irreversible inhibition of calpain and several cathepsins for dissecting platelet activation, apoptosis, neuronal injury, and cancer-related cell death. This workflow-focused guide combines dosing logic, time-resolved measurements, MEDUSA-inspired analysis, and troubleshooting to separate genuine death-pathway effects from assay artifacts.

• GW 4869: N-SMase and Exosome Research Guide

  2026-09-02

  GW 4869 hydrochloride hydrate is a cell-permeable, noncompetitive neutral sphingomyelinase inhibitor that links ceramide biology with extracellular-vesicle research. It is used as an inhibitor of exosome biogenesis and release, while lupus-nephritis evidence shows how blocking vesicle output can reduce podocyte–endothelial injury in a defined experimental model.

• Spatially Concentrated ABEs Correct PLP1 Mutations

  2026-09-01

  A Nucleic Acids Research study introduces spatially concentrated adenine base editors that improve mutation correction in oligodendrocytes without simply increasing deaminase abundance. The cABE-2.0 system combines localized TadA* recruitment with a compact Cas9 variant, correcting PLP1 A243V and improving myelination-related phenotypes while reducing transcriptome-wide RNA off-target effects.

• Reversine and the Mitotic Checkpoint: Assay Logic

  2026-09-01

  Reversine is an Aurora kinase inhibitor that can reveal how mitotic errors become cell-death signals. This article connects Aurora perturbation with Plk1-regulated checkpoint disassembly to improve mechanistic assay design and interpretation.

• Why AML Is Sensitive to Mitochondrial Drugs

  2026-08-31

  Panina and colleagues show that acute myeloid leukemia (AML) is unusually sensitive to mitochondrial-targeting drugs because of distinct defects in mitochondrial metabolism and respiratory coupling. Their combination of NCI-60 computational analysis, mitochondrial phenotyping, leukemia models, and primary AML samples also identifies strong synergy between the mitochondrial uncoupler CCCP and glycolytic inhibitor 2-deoxyglucose, while suggesting a therapeutic window over normal blood cells.

• Doxorubicin Hydrochloride: Mechanism & Research Use

  2026-08-30

  Doxorubicin hydrochloride, also called Adriamycin HCl, is an anthracycline DNA topoisomerase II inhibitor used in cancer chemotherapy research. Its value in cell and animal studies depends on separating reproducible cytotoxicity measurements from exposure-dependent cardiotoxicity and formulation effects.

• Cationic Lipid-Enriched LNPs for mRNA Vaccines

  2026-08-29

  This 2025 study evaluates whether adding the cationic lipid DOTAP to ALC-0315-based lipid nanoparticles can shift intramuscular mRNA expression toward the injection site while limiting hepatic expression. The results show that modest DOTAP incorporation improved local reporter expression and produced a transient prime-dose antibody advantage, but did not deliver a sustained immunogenicity benefit after boosting.

• Syringin Enhances Sunitinib in Renal Cell Carcinoma

  2026-08-29

  A 2024 Journal of Functional Foods study identifies Syringin as a potential adjunct to Sunitinib in renal cell carcinoma (RCC). By combining network pharmacology, molecular docking, bioinformatics, and cell-based validation, the authors link Syringin activity to EGFR/PI3K/Akt signaling, reduced RCC aggressiveness, and greater Sunitinib sensitivity.

• CCC, Ferroptosis, and TM3 Leydig Cell Growth

  2026-08-28

  Wang and colleagues identified ferroptosis-initiated inflammation as a major contributor to chlormequat chloride-induced growth inhibition in TM3 Leydig cells. Their pharmacological rescue and ferritin light-chain experiments connect lipid peroxidation, inflammatory signaling, and impaired cell viability, while also showing why viability measurements should be interpreted with orthogonal mechanistic assays.

• AP20187: A Decision Framework for Conditional Signaling

  2026-08-28

  AP20187 is a chemical inducer of dimerization that converts engineered protein interactions into controllable cellular signals. This guide presents an assay-centered framework linking conditional signaling to microenvironment-aware studies of senescent cancer-associated fibroblasts and NK-cell function.

• Bradford Protein Assay Kit: Practical Workflow

  2026-08-27

  The Bradford Protein Assay Kit (K4103) provides a fast colorimetric method for protein concentration measurement from small sample volumes. It is suited to routine protein quantification in compatible buffers, but samples containing substantial detergent or unusual buffer components require validation before use.

• ER Stress, GRP78/ATF6/CHOP, and Intestinal Stem Cells

  2026-08-27

  This version 1 study links tunicamycin-induced endoplasmic reticulum stress with intestinal stem-cell depletion, impaired epithelial differentiation, reduced crypt proliferation, and increased apoptosis in mice. Its main contribution is a connected model in which GRP78/ATF6/CHOP activation and p44/42 MAPK inhibition accompany damage to the small-intestinal stem-cell niche and barrier.

• ER-Fusogenic Liposomes Strengthen Antitumor Vaccines

  2026-08-26

  The reference study introduces phosphatidylinositol-based immunomodulatory nanoliposomes that combine intrinsic adjuvant activity with endoplasmic-reticulum membrane fusion. In murine models, OVA-loaded PI-INLs enhanced CD8 T-cell responses and tumor protection relative to MF59-adjuvanted OVA, supporting a self-adjuvanting strategy for cellular cancer vaccines.

454 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page